<DOC>
	<DOCNO>NCT01842191</DOCNO>
	<brief_summary>The aim present work evaluate efficacy fish oil supplementation serum proinflammatory cytokine level , oxidative stress marker disease progression MS .</brief_summary>
	<brief_title>Efficacy Fish Oil Multiple Sclerosis</brief_title>
	<detailed_description>Current research finding suggest Omega-3 polyunsaturated fatty acid ( PUFA ) eicosahexanoic acid ( EPA ) docosahexaenoic acid ( DHA ) contain fish oil may anti-inflammatory , antioxidant neuroprotective effect . The aim present work evaluate efficacy fish oil supplementation serum proinflammatory cytokine level , oxidative stress marker disease progression MS. 50 patient relapsing-remitting MS enrol . The experimental group receive orally 4 g/day fish oil 12 month . The primary outcome serum TNFα level ; Secondary outcomes IL-1β , IL-6 , nitric oxide catabolites , lipoperoxides , progression expand disability status scale ( EDSS ) annualized relapse rate ( ARR ) .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Titanium dioxide</mesh_term>
	<criteria>Patients clinically definite magnetic resonance image support MS Had least one relapse year entry study EDSS score 05 Treated subcutaneous 250 μg interferon beta1b ( Betaseron , Bayer ) take another supplement progressive form MS history severe depression history acute liver renal dysfunction history tobacco , drug alcohol abuse intolerance , contraindication allergy fish oil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>R-R MS</keyword>
</DOC>